Scarica l'app Stockscreener
12.18
2.40%
-0.30
Dopo l'orario di chiusura:
12.18
Precedente Chiudi:
$12.48
Aprire:
$12.38
Volume 24 ore:
684.98K
Relative Volume:
0.84
Capitalizzazione di mercato:
$779.04M
Reddito:
$262.60M
Utile/perdita netta:
$-80.80M
Rapporto P/E:
-10.02
EPS:
-1.2161
Flusso di cassa netto:
$-275.70M
1 W Prestazione:
-10.44%
1M Prestazione:
+4.55%
6M Prestazione:
+57.36%
1 anno Prestazione:
+42.46%
Intervallo 1D:
$11.92
$12.70
Intervallo di 1 settimana:
$11.92
$14.51
Portata 52W:
$5.90
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
12.18 | 779.04M | 262.60M | -80.80M | -275.70M | -1.2161 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-10-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-09-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Downgrade | Truist | Buy → Hold |
| 2025-05-02 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-02 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
ARVN SEC FilingsArvinas 10-K, 10-Q, 8-K Forms - Stock Titan
Goldman Sachs Downgrades Arvinas (ARVN) - MSN
Investor Mood: Can Arvinas Inc outperform in the next rally2026 Weekly Recap & Long-Term Safe Return Strategies - baoquankhu1.vn
Arvinas (ARVN) corrects CEO equity grant to 147,179 RSUs in Form 4/A - Stock Titan
Arvinas (NASDAQ:ARVN) Shares Down 7.8%What's Next? - MarketBeat
Arvinas to present ARV-102 Parkinson’s trial data at conference By Investing.com - Investing.com Nigeria
Arvinas, Inc. to Present Phase 1 Trial Data on ARV-102 for Parkinson’s Disease at AD/PD 2026 Conference - Quiver Quantitative
Arvinas to present ARV-102 Parkinson’s trial data at conference - Investing.com
Early ARV-102 Parkinson’s data to debut at Alzheimer’s-Parkinson’s conference - Stock Titan
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference - MarketBeat
Arvinas (NASDAQ:ARVN) Sets New 12-Month High on Insider Buying Activity - MarketBeat
Arvinas Stock Pre-Market (+4.7%): Broad Biotech Rally on Geopolitical De-escalation, Falling Oil - Trefis
Arvinas Teases Near-Term Phase 1 Data, Eyes New Vepdegestrant Partner at Leerink Conference - MarketBeat
Insider Buying: Briggs Morrison Acquires 20,000 Shares of Arvinas Inc (ARVN) - GuruFocus
ARVN: Multiple phase I programs advance, with key data for LRRK2 and KRAS G12D degraders expected in 2024 - TradingView
Briggs Morrison Acquires 20,000 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Vanguard Group Inc. Trims Position in Arvinas, Inc. $ARVN - MarketBeat
Institution Moves: What dividend growth rate does Arvinas Inc offer2025 Macro Impact & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Why analysts remain bullish on Arvinas Inc. stock2025 Trading Recap & Accurate Buy Signal Alerts - Naître et grandir
Piper Sandler reiterates Arvinas stock rating on platform validation By Investing.com - Investing.com India
Piper Sandler reiterates Arvinas stock rating on platform validation - Investing.com South Africa
How The Arvinas (ARVN) Narrative Is Evolving With New Leadership And Key 2026 Pipeline Catalysts - Yahoo Finance
Discipline and Rules-Based Execution in ARVN Response - Stock Traders Daily
Arvinas (NASDAQ:ARVN) Given New $18.00 Price Target at Citigroup - MarketBeat
Citigroup Raises Price Target for Arvinas (ARVN) to $18.00 | ARV - GuruFocus
ARVN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Arbiter Partners Capital Management LLC Invests $3.86 Million in Arvinas, Inc. $ARVN - MarketBeat
Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference - MarketBeat
ARVN: Multiple phase I programs advance with key data and commercialization milestones ahead - TradingView
ARVN: Multiple phase 1 programs advance with key data updates expected for LRRK2, BCL6, and KRAS - TradingView
Arvinas (NASDAQ:ARVN) Director John Houston Sells 35,297 Shares - MarketBeat
Arvinas (NASDAQ: ARVN) CEO receives large stock option and RSU grants - Stock Titan
Arvinas (ARVN) CSO awarded 67,000 options and 45,000 RSUs - Stock Titan
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials - Insider Monkey
Arvinas (NASDAQ:ARVN) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
11 Best Cancer Stocks to Invest In Now - Insider Monkey
TD Cowen Health Care Conference - marketscreener.com
Arvinas Holding Company (ARVN) Gets a Hold from Morgan Stanley - The Globe and Mail
Arvinas, Inc. (ARVN) Stock Analysis: Navigating the 6.50% Upside Potential Amidst Clinical Innovations - DirectorsTalk Interviews
HC Wainwright Estimates Arvinas' Q1 Earnings (NASDAQ:ARVN) - MarketBeat
Arvinas outlines 2026 clinical data milestones and maintains cash runway into second half of 2028 amid strategic pipeline focus - MSN
Analysts Conflicted on These Healthcare Names: Akebia Therapeutics (AKBA), Idexx Laboratories (IDXX) and Arvinas Holding Company (ARVN) - The Globe and Mail
New CEO at local biotech firm is leading shift to early-stage drugs - Yale Daily News
Teel Randy, president and CEO of Arvinas, sells $58k in stock - Investing.com India
Arvinas CSO Cacace sells $43,885 in stock to cover tax obligations - Investing.com Australia
Arvinas chief accounting officer Loomis sells $13k in stock By Investing.com - Investing.com South Africa
Teel Randy, president and CEO of Arvinas, sells $58k in stock By Investing.com - Investing.com Australia
Arvinas chief accounting officer Loomis sells $13k in stock - Investing.com
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):